Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/9/2025

Risks Associated with Synthetic Peptides for Muscle Growth

Cardiovascular and Hematologic Complications

  • Dose-dependent increases in hemoglobin and hematocrit significantly elevate thrombosis risk, creating potential for stroke, pulmonary embolism, and deep vein thrombosis, as reported by the American Thoracic Society 2, 1
  • HDL cholesterol decreases in a dose-dependent manner, accelerating atherosclerotic cardiovascular disease development, according to the American Heart Association 2, 1
  • In men, testosterone-based peptides carry the most worrisome risk of accelerating prostate cancer growth, making them particularly dangerous for those with occult malignancy, as noted by the American Urological Association 2, 1

Endocrine and Metabolic Disruption

  • Virilization in women is inevitable at doses sufficient to produce muscle hypertrophy, including irreversible voice deepening, clitoral enlargement, and male-pattern hair growth, as reported by the Endocrine Society 2, 3

Musculoskeletal Paradox

  • Peptides often increase muscle mass without corresponding strength improvements, meaning users gain size but not functional capacity, as noted by the American College of Sports Medicine 1
  • Studies demonstrate lean mass increases without evidence of peripheral muscle endurance or strength enhancement, according to the National Academy of Sports Medicine 2, 1

Contamination and Quality Control Crisis

  • Approximately 15% of nutritional supplements contain undeclared prohormones and anabolic agents not listed on labels, as reported by the World Anti-Doping Agency 4, 5, 1
  • 25% of supplements purchased through US outlets are contaminated with steroids, according to the US Anti-Doping Agency 5, 1
  • Muscle-building products frequently contain prohibited selective androgen receptor modulators, aromatase inhibitors, β2-agonists, new anabolic steroids, and growth hormone-releasing peptides, as noted by the International Olympic Committee 4, 5, 1
  • Evidence suggests contamination is deliberate adulteration rather than accidental, with manufacturers spiking ineffective products to create perceived results, as reported by the British Journal of Sports Medicine 4, 5, 1

Evidence Quality Limitations

  • The evidence base for peptide safety comes primarily from medical populations rather than healthy athletes, making risk-benefit calculations particularly problematic for bodybuilding applications, as noted by the American Medical Association 1
  • No randomized controlled trials exist evaluating efficacy or safety in the target population of young male athletes, according to the National Institutes of Health 6
  • The FDA has used the principle of "unreasonable risk" for similar substances, banning them based on even small potential for harm in the absence of scientifically reliable support for benefit, as reported by the US Food and Drug Administration 6

Critical Context for Athletes with Prior PED Use

  • Pre-existing cardiovascular remodeling from prior anabolic steroid use compounds thrombotic risk, as reported by the American Heart Association 6
  • Polypharmacy effects remain unstudied, with unknown interactions between peptides and residual effects of prior substances, according to the National Academy of Sciences 6
  • The lack of pharmaceutical-grade quality control means each injection carries contamination risk, as noted by the World Health Organization 4, 5